SINOPHARM GROUP 1/5/O.N. (X2S1) — Financial Flexibility Index
SINOPHARM GROUP 1/5/O.N. (X2S1) has a Financial Flexibility Index of 0.06x as of December 2025. Free cash flow of €15.76 Billion (operating CF €14.14 Billion minus capex €1.62 Billion) represents 0% of total liabilities (€256.20 Billion). Check X2S1 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
SINOPHARM GROUP 1/5/O.N. Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for SINOPHARM GROUP 1/5/O.N. across 5 annual periods. For the full cash flow conversion analysis, see SINOPHARM GROUP 1/5/O.N. (X2S1) cash conversion ratio.
Annual Financial Flexibility Index for SINOPHARM GROUP 1/5/O.N. (2021–2025)
Year-by-year free cash flow to debt coverage for SINOPHARM GROUP 1/5/O.N.. Explore SINOPHARM GROUP 1/5/O.N. debt service capacity to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.06x | €15.76 Billion | €14.14 Billion | €256.20 Billion | ▲ +21.1% |
| 2024 | 0.05x | €13.51 Billion | €11.55 Billion | €266.14 Billion | ▼ -31.5% |
| 2023 | 0.07x | €19.51 Billion | €17.17 Billion | €263.08 Billion | ▼ -19.2% |
| 2022 | 0.09x | €23.38 Billion | €20.96 Billion | €254.71 Billion | ▲ +87.2% |
| 2021 | 0.05x | €11.56 Billion | €9.31 Billion | €235.76 Billion | — |